You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 6, 2011

Beating Cosmetic Product Registration Hurdles

Bangkok Post, Corporate Counsellor Column

On January 1, 2008, Asean member countries implemented the Asean Harmonization Cosmetics Regulation Scheme in order to harmonize a previously chaotic process. A multitude of confusing laws and procedures has now been transformed into a streamlined system with just a single category for cosmetic products and an efficient registration process.

The Thai Food and Drug Administration (FDA) implemented a new online cosmetic product registration system on November 1, 2010. Registration is now less time consuming and more environmentally friendly than under the previous paper-based system.

The FDA has also created a single product category, which forces some cosmetic companies to re-register their products. This is an important change from past practice, when there were three categories for cosmetic products.

According to the Society of Cosmetic Chemists of Thailand, the local cosmetic industry has been growing by 10 to 20 percent per year over the last ten years and is expected to see 30 percent growth in the domestic market in 2011. This domestic trend mirrors similar rapid growth in cosmetic imports.

Clearly, Thailand is becoming an extremely attractive place for cosmetic product distributors to do business. As the industry continues to expand, cosmetics distributors new to the market should be aware of possible hurdles that typically arise during the FDA product registration process. By preparing effectively, applicants will be able to save costs and bring their products to market quickly.

Product Name

Cosmetic products rely mainly on the name of the product to attract consumers. This has proven to be a very effective method for marketing the products, since this is the first element that consumers look at when electing to purchase a product.

Therefore, distributors need to take the utmost care when naming their products, prior to applying for product registration in Thailand. To avoid rejection by the FDA, each word in the product name must correctly reflect the objective of the product, and the words used must not mislead consumers.

One difficulty faced by companies is using product names that differ from the ingredients or the purpose of the product. For example, if the product name is “TRADENAME Tanning Body Lotion” but the product formula contains no ingredients that act as a tanning agent, this product will be declined registration by the FDA.

The manufacturer or importer must also exercise care in regard to the choice of a product name to avoid it being deemed an overclaim or use of homophonous words.

For example, a product used to combat wrinkles is called “TRADENAME Eraser Wrinkle Serum”. The word “eraser” will not be permitted for use in the product name because, in reality, the product cannot erase wrinkles. FDA officials would therefore deem the product name to be an overclaim.

Use of a homophonous word for a prohibited or improper word in a product name is also impermissible. An example of this is “Btox”, which is derived from the prohibited word “Botox”. “Btox” would be denied registration by the FDA because it is confusingly similar to the registered trademark BOTOX and is deemed an infringement.

Finally, scientific words such as “nano” are not recommended, as additional scientific or reliable supporting documents for those words must be submitted to the FDA to support the claimed correlation.

Formula

The use of a prohibited ingredient in a formula will definitely lead to a rejection by the FDA, and the manufacturer will be required to alter the product formula to secure FDA approval. Examples of prohibited ingredients commonly found in cosmetics are dimethylamine and diethylene glycol.

Some ingredients are authorized but restricted, and these ingredients are thus required to comply with special FDA rules. For example, a hair product formula for curling or straightening hair must not include tetraborates in an amount exceeding 8 percent, whereas a bath product formula must not exceed 18 percent (both are calculated in boric acid form).

A formula containing some specially controlled ingredients, especially natural extracts, must have a product safety document. For example, Citrus Reticulata Peel oil has no restrictions on the amount used in a formula. However, the total concentration of furocoumarin (found in this extract) in a finished cosmetic product must not exceed 1 ppm. Therefore, the company must certify the safety assessment of the product and provide an analysis of the amount of furocoumarin in the finished product.

FDA Cosmetic Category Codes

In the cosmetic registration process, an applicant is required to choose a cosmetic category code for each product from an FDA database known as the “Cosmetic Data Dictionary.”

For example, if the product is a facial makeup set consisting of compact face powder with foundation, sunscreen, and lip gloss, the cosmetic category code would be 12796. If this code is not clearly specified, the characteristics or product type may result in selection of the wrong cosmetic category code, which would lead to the application being rejected by the Examiner.

As the examples above illustrate, it is important that companies pay keen attention to the preparation of the registration of their product and advertising, as this will ensure a smooth and unhindered product launch.

 

RELATED INSIGHTS​ 

October 15, 2025
The Indonesian Food and Drug Administration (BPOM) has introduced more stringent oversight of health supplements containing probiotics with new guidelines that require clinical trials for certain products and expanded documentation standards. BPOM Regulation No. 17 of 2025 replaces the previous 2021 regulation and establishes a comprehensive framework for evaluating probiotic strains used in health supplements. Assessment Requirements The new regulation expands the scope of assessment to include not only categorization and documentation but also technical procedures, strain classification, and clinical trial requirements. Unlike the previous regulation, which provided general guidance, the updated framework creates a comprehensive system for evaluating both registered probiotic strains and new or combined strains. Manufacturers must now submit supporting documentation covering strain identification and functional characterization, safety, efficacy, and product quality. The previous regulation required documentation only on safety, efficacy, and quality. Clinical Trials One of the most significant changes is the requirement for clinical trials conducted in Indonesia for applications that include benefit claims other than maintaining digestive health, or where there are modifications to benefit claims. The regulation specifies that phase 1 trials must demonstrate safety, while phase 2 trials must validate efficacy using statistically valid methods such as double-blind, randomized, placebo-controlled studies). In addition, phase 3 and phase 4 trials may be required, and postmarket surveillance data must be submitted. Technical Assessment Framework Annex 4, a newly introduced section, establishes technical procedures for assessing health supplements containing probiotics in Indonesia. This comprehensive framework outlines criteria for evaluating new probiotic strains, including strain identification, functional characterization, safety, efficacy, and product quality. The annex introduces a clear classification of claims for health supplement products containing probiotics: General claims(e.g., maintaining digestive health). Functional claims(e.g., normal biological function or activity in the body). Risk reduction claims(e.g., lowering disease risk). The regulation restricts use of the term
October 3, 2025
On September 26, 2025, the Contract Committee under Thailand’s Consumer Protection Board issued a regulation that aims to standardize contracts and enhance consumer protection within the beauty and wellness industry. The Notification on Prescribing the Beauty Service Business as a Contract-Controlled Business B.E. 2568 (2025), which takes effect on January 24, 2026, requires business operators to use a prescribed standard contract in Thai and adhere to strict mandatory provisions and prohibitions. These regulations apply to operators across all in-person and online service channels, including via digital platforms. “Beauty services business” is defined as the provision of services under an agreement allowing consumers to receive a series of treatments, either over a set number of sessions or within a set period. This includes massage, spa, other methods for cleanliness, beauty, or care of facial or body skin, and weight control and body shaping—including services offered electronically. The law excludes surgery, liposuction, and medical treatments performed by licensed practitioners. The notification establishes the following key requirements: Mandatory contract and formatting. All contracts with consumers must use the standard contract form, in Thai, with clear, readable text (minimum font size of 2 millimeters, no more than 11 characters per inch), and include all essential terms from the annexed form. Contract execution. Contracts must be made in duplicate, with one copy given to the consumer at signing. For agreements concluded through electronic channels, the process must comply with the Electronic Transactions Act and use the same required terms. Digital platforms. Business operators who provide services facilitated through a digital platform as an intermediary are ultimately responsible for ensuring the consumer receives a compliant contract. Prohibited clauses. The law prohibits clauses that limit or exclude liability for damages to life, body, health, mind, or property resulting from breach of contract or a wrongful act;
September 16, 2025
Since Thailand formally removed Mitragyna speciosa (kratom) from the list of narcotic drugs, the country has progressed from outright prohibition to a structured, license-based regime. While the Ministry of Public Health oversees cannabis plant regulation, the Ministry of Justice (MOJ) is the regulatory authority overseeing kratom plants. For the avoidance of doubt, separate Ministry of Public Health notifications prohibit the use of kratom as a food ingredient unless a food safety evaluation has been conducted; however, this restriction does not affect trade in unprocessed leaves per se. For businesses in Thailand dealing exclusively in kratom leaves, the most consequential development is the Ministerial Regulation on the Application for Permits and Notifications for the Importation and Exportation of Kratom Leaves B.E. 2568 (2025), a bylaw of the Kratom Plant Act 2022. The ministerial regulation establishes the following notable definitions: “Kratom leaves”: Fresh or dried leaves in their natural, unprocessed state (no extracts, concentrates, or infused products). “Import/Export”: Any act of bringing kratom leaves into or out of Thailand, whether for commercial sale, industrial processing abroad, or research. Import/Export Licensing Under the Kratom Plant Act, a license is mandatory for importing or exporting kratom leaves. Individuals, juristic persons, community enterprises, and state agencies in Thailand are eligible to obtain a license to import (or a license to export) kratom leaves. Licenses are available to qualified individuals and juristic persons. Individuals must satisfy the following qualifications to be eligible for a license: Thai nationality, ≥ 20 years old, resident in Thailand. Not incompetent, quasi-incompetent, or under legal guardianship. No license suspension currently in force under the Kratom Act or Narcotics Code. No license revocation in the previous two years. No conviction under the Kratom Act or Narcotics Code within the previous two years (unless fully released from punishment). Juristic persons must satisfy
September 4, 2025
With advancements in health technology, telemedicine has taken on a wider online presence in Thailand. Under the Medical Facility Act, licensed clinics and hospitals may now diagnose, prescribe, and issue electronic prescriptions during a video call, provided they maintain patient confidentiality and proper recordkeeping. As a complementary concept, a telepharmacy allows a pharmacist to verify prescriptions, counsel patients, and dispense medication from a remote site. Hospitals, clinic chains, and some retail pharmacy groups have adopted “drive-thru” or “locker” pick-up points where drugs are bagged only after a real-time video consultation with a registered pharmacist. The clear benefits of telehealth include shorter waiting times and broader access to specialists, which is in the public interest. Drug Distribution and Advertising in Thailand The online pharmacy ecosystem creates a legal bridge in that once a teleconsulting doctor issues an e-prescription, a licensed pharmacy can lawfully dispense and deliver the medicine prescribed to the patient’s door. Nonetheless, the critical compliance component remains the advertising of medicinal drugs. It is still not allowed to advertise prescription/pharmacy-dispensed drugs to the public in Thailand. Although Thailand’s Drug Act of 1967 was written more than half a century ago, it still governs the trading of every medicinal drug that makes its way to consumers in Thailand—whether bought at a pharmacy or delivered with a few taps on a smartphone. First and foremost, the pharmacy must hold a license to sell medicinal drugs as a retailer. It is also mandatory that arrangements be made for a pharmacist to be on duty during opening hours. Drugs are classified into three main categories: prescription drugs, pharmacy-dispensed drugs, and over-the-counter (OTC) drugs. The listing of OTC drugs with their prices via an online platform is allowed, as only OTC drugs may be advertised directly to the public. However, naming or showing